Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Jane Peters"'
Autor:
James W.A. Ritchie, Sarah E. Halford, Harpreet Singh-Jasuja, Oliver Schoor, Karen Hill, Jane Peters, Lesley McGuigan, Norbert Hilf, Sarah Kutscher, Juha Lindner, Willie Stewart, Alan Jackson, Sarah Jefferies, Catherine McBain, Christopher J. Twelves, Omar Al-Salihi, Allan James, Paul J. Mulholland, Sharon Peoples, Roy Rampling
Supplementary Table S1. TUMAPs contained in IMA950 and associated source antigens. Supplementary Table S2. Statistical analysis underlying the recruitment of 20 immune evaluable patients per cohort. Supplementary Table S3. Reasons for HLA-A*02 positi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35bb952ed2561cc6de3f0f7698d8e249
https://doi.org/10.1158/1078-0432.22468137.v1
https://doi.org/10.1158/1078-0432.22468137.v1
Autor:
James W.A. Ritchie, Sarah E. Halford, Harpreet Singh-Jasuja, Oliver Schoor, Karen Hill, Jane Peters, Lesley McGuigan, Norbert Hilf, Sarah Kutscher, Juha Lindner, Willie Stewart, Alan Jackson, Sarah Jefferies, Catherine McBain, Christopher J. Twelves, Omar Al-Salihi, Allan James, Paul J. Mulholland, Sharon Peoples, Roy Rampling
Purpose: To perform a two-cohort, phase I safety and immunogenicity study of IMA950 in addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma. IMA950 is a novel glioblastoma-specific therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24176b5389b980038b76490af7d1161f
https://doi.org/10.1158/1078-0432.c.6526851.v1
https://doi.org/10.1158/1078-0432.c.6526851.v1
Autor:
Ruth R. French, Shirley Jane Peters, Mark S. Cragg, David P. Humphreys, IC Mockridge, Sonya James, Alison Turner, Robert J. Oldham, Tania F. Rowley, Stephen A. Beers, Joshua M. Sopp
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Communications Biology
Communications Biology
The majority of depleting monoclonal antibody (mAb) drugs elicit responses via Fc-FcγR and Fc-C1q interactions. Optimal C1q interaction is achieved through hexameric Fc:Fc interactions at the target cell surface. Herein is described an approach to e
Autor:
Sonia Iyer, James Conway, Deanna Russell, Avinash Reddy, Jan Cosaert, Simon Barry, Marlene Dressman, Ilhem Mensi, Boaz Aronson, Jane Peters, Helen Ambrose, Keunchil Park, Patrick Forde, Benjamin Besse, John V. Heymach, J. Carl Barrett
Publikováno v:
Cancer Research. 83:CT039-CT039
Background: Promising clinical activity has been described with the combination of ceralasertib (oral ATR inhibitor) and durvalumab (anti-PD-L1 mAb) in patients with NSCLC who have progressed on prior anti-PD-(L)1 immunotherapy (HUDSON, NCT03334617)
Autor:
Amy K Sawtell, Laura E Starkie, Shirley Jane Peters, Breda Twomey, Clare L. Thompson, Pallavi Bhatta, Emily Barry, Milena Mennecozzi, Stephen Edward Rapecki, Ahmad M Kamal, Kevin Whale, Helene Margaret Finney, David Alan Cook
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Bispecific antibodies can uniquely influence cellular responses, but selecting target combinations for optimal functional activity remains challenging. Here we describe a high-throughput, combinatorial, phenotypic screening approach using a new bispe
Autor:
Oliver Zaccheo, Hanna Hailu, Shirley Jane Peters, Frank R. Brennan, Eleanor J. Ward, Rona M. Cutler, Andrew M. Ventom, Nicola L. Davies, David P. Humphreys, Farnaz Fallah-Arani, Thomas L. Pither, Tania F. Rowley, Gianluca Fossati, Louise J. Healy, Joshua M. Sopp, Mike Aylott, Katharine Cain, Alison Eddleston, John Sherington, Robert J. Griffin
Publikováno v:
Communications Biology, Vol 1, Iss 1, Pp 1-12 (2018)
Autoantibody-mediated diseases are currently treated with intravenous immunoglobulin, which is thought to act in part via blockade of Fc gamma receptors, thereby inhibiting autoantibody effector functions and subsequent pathology. We aimed to develop
Publikováno v:
Journal of Child Health Care. 23:242-255
Infant mental health (IMH) is a growing area of practice for health, education and social care practitioners, as links are increasingly made between experiences in the early years and subsequent child development, mental health and well-being. It is
Autor:
Kevin Greenslade, H Björkelund, Alison Eddleston, Bryan Smith, Jay Tibbitts, S Crilly, F Junker, Michael D.J. Parkinson, Andrea Kiessling, Robert J. Griffin, Joanne E. Compson, Katharine Cain, Omar Qureshi, Frank R. Brennan, David P. Humphreys, Shirley Jane Peters, Farnaz Fallah-Arani, M Malmqvist, Louis Christodoulou, Nicola L. Davies, L Staelens, E. Ward, Tania F. Rowley, Thomas L. Pither
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-15 (2017)
Scientific Reports
Scientific Reports
Engagement of Fcγ-receptors triggers a range of downstream signalling events resulting in a diverse array of immune functions. As a result, blockade of Fc-mediated function is an important strategy for the control of several autoimmune and inflammat
Autor:
Paul Mulholland, Oliver Schoor, Omar Al-Salihi, Chris Twelves, Juha Lindner, Harpreet Singh-Jasuja, Sharon Peoples, Alan Jackson, Sarah Halford, James W A Ritchie, Lesley McGuigan, Catherine McBain, Roy Rampling, Sarah Kutscher, Allan James, Willie Stewart, Norbert Hilf, Jane Peters, Sarah Jefferies, Karen Hill
Publikováno v:
Clinical Cancer Research. 22:4776-4785
Purpose: To perform a two-cohort, phase I safety and immunogenicity study of IMA950 in addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma. IMA950 is a novel glioblastoma-specific therapeutic
Autor:
David P. Humphreys, Richard J. K. Taylor, Rachel A. Garlish, Shirley Jane Peters, Perdita E. Barran, Kamila J. Pacholarz, Alistair James Henry
Publikováno v:
Pacholarz, K, Peters, S, Garlish, R, Henry, A, Taylor, R, Humphreys, D & Barran, P 2016, ' Molecular Insights into the Thermal Stability of mAbs with Variable-Temperature Ion-Mobility Mass Spectrometry ', ChemBioChem: a European journal of chemical biology . https://doi.org/10.1002/cbic.201500574
The aggregation of protein-based therapeutics such as monoclonal antibodies (mAbs) can affect the efficacy of the treatment and can even induce effects that are adverse to the patient. Protein engineering is used to shift the mAb away from an aggrega